AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17443036
Drug: NSAID-ET (NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID-ET (NSAID plus etizolam 0.5 mg)
Trial: 17443036
Drug: NSAID (mefenamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (mefenamic acid 250 mg)
Trial: 16046372
Drug: CCK‐4 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐4 injection
Trial: 12032191
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg o.d.
Trial: 10188113
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam 0.025 mg/kg
Trial: 8540943
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose infusion at 180 mL/h (9 g/h)
Trial: 31710398
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil
Trial: 12479119
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection
Trial: 30206130
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) at 2 L/kg/min
Trial: 30206130
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) at 1 L/kg/min
Trial: 23980043
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding with enteral nutrition
Trial: 21366964
Drug: MSM+EDTA lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSM+EDTA lotion
Trial: 17684963
Drug: Epoetin and
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin and iron preparations
Trial: 17684963
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of epoetin and parenteral iron preparations
Trial: 15173493
Drug: Nedocromil 16
RxNorm normalized name: NEDOCROMIL
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil 16 mg/day
Trial: 6242073
Drug: Oral tetracyclines
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracyclines 500 mg b.i.d.
Trial: 29617739
Drug: RBX2660 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 (2 doses)
Trial: 29617739
Drug: RBX2660 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 (1 dose) followed by Placebo (1 dose)
Trial: 29617739
Drug: RBX2660 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 (1 dose)
Trial: 27046798
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose antithrombin (3000 IU/daily)
Trial: 22185431
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 2 hours post-dose
Trial: 22185431
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 6 hours post-dose
Trial: 22185431
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 10 hours post-dose
Trial: 22185431
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with no washing
Trial: 24527596
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy
Trial: 17912169
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow stem cell therapy (BM-derived cells injected into infarcted hearts)
Trial: 19239460
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg)
Trial: 8780347
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg gastric-delivery-system (GDS) iron supplement
Trial: 8780347
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg conventional (Con) iron supplement
Trial: 28856398
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of SSRIs (last tablet noted ≤ 7 days before diagnosis)
Trial: 28856398
Drug: Late use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late use of SSRIs (last tablet noted ≥ 8 days before diagnosis)
Trial: 21175345
Drug: Older ovariectomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older ovariectomized rats receiving exogenous estrogen treatment (17-β-estradiol)
Trial: 21175345
Drug: Modulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modulation of estrogen status in 1-year-old animals (e.g., ovariectomy or continuous exposure to estrogen)
Trial: 11392363
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) at half dose
Trial: 8276557
Drug: Enoxaparin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (20 mg daily, starting 2 hours before surgery)
Trial: 8276557
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (2 doses of 0.2 ml daily, starting 2 hours before surgery)
Trial: 3524744
Drug: Intramuscular chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chloroquine diphosphate, 2.5 mg base/kg at 0, 1, 12, 13, 24, and 25 hours
Trial: 3524744
Drug: Subcutaneous chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous chloroquine diphosphate, 5 mg base/kg at 0, 12, and 24 hours
Trial: 3524744
Drug: Intramuscular chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chloroquine diphosphate
Trial: 3524744
Drug: Subcutaneous chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous chloroquine diphosphate
Trial: 28618198
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol pre-emptive analgesia (15 mg/kg before treatment)
Trial: 28618198
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol preventive analgesia (15 mg/kg at the end of treatment)
Trial: 28618198
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol pre-emptive analgesia
Trial: 25306220
Drug: Individualised best
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised best practice ergonomic intervention plus 3×20 minute weekly, progressive neck/shoulder girdle exercise group sessions for 12 weeks.
Trial: 25306220
Drug: Individualised best
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised best practice ergonomic intervention plus 1‐hour weekly health information sessions for 12 weeks.
Trial: 30943497
Drug: Bromazepam 3
RxNorm normalized name: bromazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 3 mg
Trial: 7713242
Drug: Methazolamide 50
RxNorm normalized name: methazolamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide 50 mg q.i.d. for 2 weeks
Trial: 28662531
Drug: Maximal leg
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal leg strength program (80-95% of 1-RM, 1-3 repetitions, 3-6 sets, 3-4 min rest between sets) performed twice a week for 10 weeks.
Trial: 25366615
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/day with enteral nutrition (EN) and parenteral nutrition (PN)
Trial: 21431373
Drug: Single high‐dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high‐dosage extracorporeal shockwave therapy (0.3 mJ/mm(2))
Trial: 21431373
Drug: Two sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sessions of low‐dosage extracorporeal shockwave therapy (0.2 mJ/mm(2))
Trial: 16691091
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT; mainly spinal mobilization)
Trial: 16691091
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT; mainly exercise therapy)
Trial: 16691091
Drug: Continued care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued care by the general practitioner (GP; analgesics, counseling and education)
Trial: 1405268
Drug: Intravenous large
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous large dose streptokinase
Trial: 3894494
Drug: Cimetidine (Tagamet)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (Tagamet) 300 mg q.i.d.
Trial: 3894494
Drug: Mylanta II
RxNorm normalized name: Mylanta II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylanta II 10 ml q.i.d.
Trial: 28165762
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 1-6 mg daily
Trial: 18419443
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B inhalation (twice a week until neutrophil counts >300 cells/mm3)
Trial: 18419443
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B inhalation (on-treatment analysis)
Trial: 18419443
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation (on-treatment analysis)
Trial: 16850791
Drug: Restoration treatment
RxNorm normalized name: CALCIUM 0.55 ORAL TABLET [Restoration Treatment]
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restoration treatment
Trial: 8792943
Drug: Prescription medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription medications (self-reported use)
Trial: 8792943
Drug: Gender comparison
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender comparison in medication use
Trial: 8792943
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with greater medication use
Trial: 8792943
Drug: Age-related medication
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-related medication use
Trial: 8792943
Drug: Gender-related medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-related medication use
Trial: 1634705
Drug: Milacemide 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 1200 mg/day for 1 month
Trial: 2164477
Drug: Metoprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta 1-selective blocker)
Trial: 6326999
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy and chemotherapy
Trial: 29441742
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) combined with low-dose corticosteroids
Trial: 29441742
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) combined with low-dose corticosteroids
Trial: 25765590
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg (maximum 100 mg) subcutaneously every 12 hours for 30 days
Trial: 25765590
Drug: Traditional anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anticoagulation (intravenous heparin followed by oral warfarin for 3 months)
Trial: 21183917
Drug: Omaron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaron (25 mg of cinnarizine and 400 mg of piracetam), 1 tablet 3 times a day for 12 weeks
Trial: 16688202
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) at 3, 4, and 5 l/min
Trial: 12568837
Drug: L‐carnitine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐carnitine therapy 2 g/day
Trial: 9816321
Drug: UFT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT at a dose of 400 mg/m2/day administered as three divided doses (every 8 h)
Trial: 9816321
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosing of UFT
Trial: 9816321
Drug: UFT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT at a dose of 300 mg/m2/day
Trial: 9816321
Drug: UFT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT at a dose of 400 mg/m2/day
Trial: 1466210
Drug: Brotizolam 0.25-0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.25-0.50 mg sublingually
Trial: 1466210
Drug: Diazepam 5-10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5-10 mg orally
Trial: 6717216
Drug: Moxalactam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (30 mg/kg) for 3 doses postoperatively
Trial: 6717216
Drug: Moxalactam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (30 mg/kg) for 6 doses postoperatively
Trial: 25825138
Drug: Compressive cryotherapy
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compressive cryotherapy (CC)
Trial: 23370528
Drug: L-Name (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Name (20 μg min⁻¹ kg⁻¹) during OGTT
Trial: 23370528
Drug: L-Name (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Name (at rates of 2.5, 5, 10 and 20 μg min⁻¹ kg⁻¹) during hyperglycaemic clamps
Trial: 22214253
Drug: Eucommia extract
RxNorm normalized name: Eucommia ulmoides bark extract
DrugBank: Eucommia ulmoides bark (DB14259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucommia extract 500 mg three times daily for eight weeks
Trial: 22214253
Drug: Eucommia extract
RxNorm normalized name: Eucommia ulmoides bark extract
DrugBank: Eucommia ulmoides bark (DB14259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucommia extract 1 g three times daily for two weeks
Trial: 19597364
Drug: Psychodynamic Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic Group Therapy (PGT) plus clonazepam
Trial: 11669470
Drug: Remifentanil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (target plasma concentrations: 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml)
Trial: 9721772
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogen (n = 20)
Trial: 9721772
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of simvastatin (n = 18)
Trial: 9721772
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n = 17)
Trial: 958162
Drug: Porfiromycin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porfiromycin (75 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Trial: 958162
Drug: Mitomycin-C (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (22.5 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Trial: 21168536
Drug: teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriparatide 20 μg/day
Trial: 23647283
Drug: Self-help treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help treatment administered in a group
Trial: 9411464
Drug: Longer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer treatment duration
Trial: 18154644
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral morphine (SRM)
Trial: 9247842
Drug: Oral tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolterodine 3.2 mg
Trial: 9247842
Drug: Oral tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolterodine 6.4 mg
Trial: 9247842
Drug: Oral tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolterodine 12.8 mg
Trial: 9247842
Drug: Oral tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolterodine (14C) 5 mg
Trial: 7682488
Drug: L-carnitine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (6 g daily)
Trial: 6180562
Drug: Propafenone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (900 mg daily)
Trial: 7682488
Drug: Propafenone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (900 mg daily) plus L-carnitine (6 g daily)
Trial: 3117401
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 20‐30 mg adriamycin for 4 weeks or 2 years
Trial: 3117401
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 20 mg mitomycin C for 4 weeks or 2 years
Trial: 31870492
Drug: Intracoronary tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary tenecteplase (TNK) 4 mg
Trial: 24865871
Drug: Parent-focused treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-focused treatment (PFT)
Trial: 29480503
Drug: Community-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based treatment as usual (TAU)
Trial: 19787711
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy (continence pessary, pelvic floor muscle training or combined)
Trial: 14581122
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment with gabapentin
Trial: 10809260
Drug: Dopamine (4-hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Trial: 10809260
Drug: Dobutamine (4-hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Trial: 7768249
Drug: Loxiglumide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (10 mg.kg‐1.h‐1)
Trial: 9071422
Drug: Azithromycin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 2.0 g orally
Trial: 6303490
Drug: Ceftriaxone 250
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 250 mg intramuscularly
Trial: 25600977
Drug: Low C-form
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low C-form (10 mg lenvatinib, <4% crystalline)
Trial: 25600977
Drug: High C-form
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High C-form (10 mg lenvatinib, 38% crystalline)
Trial: 25600977
Drug: Reference C-form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference C-form (10 mg lenvatinib, 15% crystalline)
Trial: 10874974
Drug: Intraarterial chemoperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial chemoperfusion (CP) with mitoxantrone (820 mg/m2 for 1-2 hours)
Trial: 10874974
Drug: Intraarterial embolization
RxNorm normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial embolization therapy (ET) using Histoacryl or Ethibloc
Trial: 7594333
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Trial: 7594333
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Trial: 2102066
Drug: kanamycin sulphate
RxNorm normalized name: Kanamycin sulphate
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: kanamycin sulphate alternated to polydeoxyribonucleotide vaginal suppositories